NeuroPace Inc engages clinicians on RNS System for refractory seizures at ASSFN

NeuroPace Inc engages clinicians on RNS System for refractory seizures at ASSFN
NeuroPace Inc promotes RNS System

NeuroPace Inc is actively presenting its RNS System for the treatment of drug-resistant focal epilepsy at the ASSFN conference, encouraging attendees to visit Booth 107 and interact with its clinical team.

The RNS System is indicated as adjunctive therapy for adults with refractory, partial onset seizures and is offered on a prescription-only basis.

A recent study published in the Green Journal showed long-term benefits of the RNS System for patients with drug-resistant epilepsy, according to company disclosures. In the first quarter of 2026, NeuroPace reported revenue of $22.1 million, with RNS System sales growing 20% year over year and full-year guidance increased following the results. The company continues to focus on the prescription-only device as part of its commercial strategy.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.